Open Access Articles- Top Results for Risedronic acid

Risedronic acid

Risedronic acid
Systematic (IUPAC) name
(1-hydroxy-1-phosphono-2-pyridin-3-yl-ethyl)phosphonic acid
Clinical data
AHFS/ International Drug Names
  • AU: B3
  • US: C (Risk not ruled out)
Pharmacokinetic data
Bioavailability 0.63%
Protein binding ~24%
Metabolism None
Half-life 1.5 h
Excretion Renal and fecal
105462-24-6 7pxY
PubChem CID 5245
DrugBank DB00884 7pxN
ChemSpider 5055 7pxN
UNII KM2Z91756Z 7pxN
Chemical data
Formula C7H11NO7P2
283.112 g/mol
 14pxN (what is this?)  (verify)

Risedronic acid (INN) often used as its sodium salt risedronate sodium (USAN) is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. It is produced and marketed by Warner Chilcott, Sanofi-Aventis, and in Japan by Takeda under the trade names Actonel, Atelvia, and Benet. It is also available in a preparation that includes a calcium carbonate supplement, as Actonel with Calcium.


Risedronate is taken orally, usually weekly or monthly. Notably, if risedronate lodges in the esophagus, it can lead to esophageal ulcers. Therefore, it is recommended that risedronate be taken with the body upright, and followed by a glass of water. Moreover, risedronate is poorly absorbed when taken with food, so it is recommended that no food or drink other than water be taken for 2 hours before and 30 minutes after taking risedronate. Risedronate has a faster esophageal transit time and different chemical chain which results in less gastrointestinal side-effects than other drugs in this class. The dosage instructions also show that risedronate can be taken with less water than other drugs in the class. Risedronate is also available as a 75 mg tablet to be taken on two consecutive days each month (2CDM) in order to optimize patient adherence. This formulation has been studied in a randomized, double-blind, parallel-group, multinational trial in 1229 postmenopausal women with osteoporosis.[1]


In January 2006 P&G and its marketing partner Sanofi-Aventis filed a Lanham Act false claims lawsuit against rival drugmakers Roche and GlaxoSmithKline claiming false advertising about Boniva.[2] The manufacturers of Boniva, a rival bisphosphonate, were accused in the suit of causing a "serious public health risk" through misrepresentation of scientific findings. In a ruling on September 7, 2006 U.S. District Judge Paul A. Crotty rejected P&G's attempted injunction. P&G was criticized for attempting to "preserve its market share by denigrating Boniva". Judge Crotty wrote that "Roche was clearly entitled to respond with its own data, provided that the data was truthfully and accurately presented".[3]

In 2006, P&G faced controversy over its handling of clinical research involving risedronate (News Reports[4] and discussion).[5]

In common with other bisphosphonate drugs, risedronate appears to be associated with the rare side effect osteonecrosis of the jaw, often preceded by dental procedures inducing trauma to the bone.

See also


External links